Clinical Trials Directory

Trials / Completed

CompletedNCT05743361

Security Efficacy COVID-19 Vaccination

Studio Sierologico in Volontari Vaccinati Contro COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
540 (actual)
Sponsor
Istituto Auxologico Italiano · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Preliminary data support a possible molecular mimicry between SARS-CoV-2 and autologous components. This suggests the occurrence of autoimmunity during COVID-19. Consistently, autoimmunity may occur after SARS-CoV2 vaccination. The study aims to investigate the production of autoantibodies after vaccination in healtcare workers.

Detailed description

Healtcare workers undergoing SARS-CoV-2 vaccination (with RNA-vaccines) will be included on a voluntary basis. Blood samples will be collected before and after vaccination (1 -3 - 6 - 12 months). All the vaccination side effects will be registered.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBlood samplingDetection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG

Timeline

Start date
2021-01-07
Primary completion
2021-12-31
Completion
2022-04-30
First posted
2023-02-24
Last updated
2023-02-24

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05743361. Inclusion in this directory is not an endorsement.

Security Efficacy COVID-19 Vaccination (NCT05743361) · Clinical Trials Directory